Cardiovascular Systems (CSI) said it has acquired a line of peripheral support catheters from WavePoint Medical.
The St. Paul, MN-based company said it will introduce the acquired catheters as its new ViperCross line in the first half of its fiscal year ending June 30, 2022.
CSI said as part of this transaction, WavePoint will also develop a portfolio of specialty catheters used in the treatment of chronic total occlusions (CTO) and complex percutaneous coronary intervention (PCI) procedures for CSI.
CTOs represent a significant and growing segment of PCIs and often contribute to poor patient outcomes. Commercial availability of these specialty catheters is anticipated in CSI’s fiscal year ending June 30, 2023.
“With the acquisition of these peripheral support catheters, CSI will soon offer a complete portfolio of products for the treatment of peripheral artery disease, including atherectomy, balloon catheters, guidewires, support catheters and embolic protection,” said Scott Ward, chairman, president, and CEO of CSI said. “In coronary, the successful development of a portfolio of CTO products will expand our existing offering of coronary support products. Together, these new products advance our ability to help physicians improve outcomes for patients undergoing complex peripheral and coronary interventions.”